HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sudhir Agrawal Selected Research

Cyclic AMP-Dependent Protein Kinase RIalpha Subunit

7/2002Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity.
7/2002GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sudhir Agrawal Research Topics

Disease

41Neoplasms (Cancer)
01/2021 - 01/2002
12Prostatic Neoplasms (Prostate Cancer)
02/2011 - 02/2002
5Breast Neoplasms (Breast Cancer)
11/2009 - 05/2003
4Asthma (Bronchial Asthma)
09/2007 - 03/2002
4Inflammation (Inflammations)
08/2007 - 11/2003
4Colonic Neoplasms (Colon Cancer)
07/2007 - 04/2002
3Carcinoma (Carcinomatosis)
06/2010 - 10/2004
3Hypersensitivity (Allergy)
09/2007 - 03/2002
2Melanoma (Melanoma, Malignant)
01/2021 - 04/2004
2Pancreatic Neoplasms (Pancreatic Cancer)
10/2011 - 09/2006
2Lung Neoplasms (Lung Cancer)
06/2006 - 07/2002
2Carcinogenesis
11/2005 - 11/2005
2Retinoblastoma (Glioblastoma, Retinal)
07/2004 - 09/2003
2Glioblastoma (Glioblastoma Multiforme)
05/2003 - 01/2002
1Spinocerebellar Ataxias (Spinocerebellar Ataxia)
12/2021
1Ischemia
06/2017
1Atherosclerosis
01/2017
1Hyperplasia
01/2017
1Atherosclerotic Plaque (Atheroma)
01/2017
1Infections
11/2016
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
11/2013
1Autoimmune Diseases (Autoimmune Disease)
11/2013
1Proteinuria
11/2013
1Skin Diseases (Skin Disease)
07/2013
1Psoriasis (Pustulosis Palmaris et Plantaris)
07/2013
1Necrosis
04/2013
1Neoplasm Metastasis (Metastasis)
01/2012
1Acute Radiation Syndrome
01/2012
1Colorectal Neoplasms (Colorectal Cancer)
10/2011

Drug/Important Bio-Agent (IBA)

21OligonucleotidesIBA
06/2017 - 01/2002
12Antisense OligonucleotidesIBA
12/2021 - 04/2002
12Proteins (Proteins, Gene)FDA Link
04/2013 - 02/2002
8Toll-Like Receptor 9IBA
01/2021 - 01/2006
7AndrogensIBA
02/2011 - 02/2002
6Irinotecan (Camptosar)FDA LinkGeneric
01/2006 - 01/2002
4ErbB Receptors (EGF Receptor)IBA
10/2011 - 07/2004
4VaccinesIBA
04/2010 - 03/2002
4AllergensIBA
08/2007 - 03/2002
4Pharmaceutical PreparationsIBA
12/2003 - 03/2002
4Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA
09/2003 - 02/2002
3AntigensIBA
09/2018 - 03/2002
3AntibodiesIBA
01/2012 - 03/2002
3Cetuximab (Erbitux)FDA Link
10/2011 - 01/2006
3Monoclonal AntibodiesIBA
10/2011 - 01/2006
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
11/2009 - 07/2004
3DNA (Deoxyribonucleic Acid)IBA
03/2009 - 03/2002
3Messenger RNA (mRNA)IBA
09/2006 - 10/2004
3Hormones (Hormone)IBA
02/2005 - 02/2002
3Antineoplastic Agents (Antineoplastics)IBA
10/2004 - 04/2002
2tilsotolimodIBA
01/2021 - 09/2018
2InterferonsIBA
09/2018 - 04/2013
2Nucleic AcidsIBA
11/2016 - 11/2013
2CytokinesIBA
07/2013 - 04/2013
2Interleukin-6 (Interleukin 6)IBA
04/2013 - 01/2003
2Neoplasm Antigens (Tumor Antigens)IBA
01/2012 - 06/2010
2Mitogen-Activated Protein KinasesIBA
10/2011 - 07/2004
2Prostate-Specific Antigen (Semenogelase)IBA
02/2011 - 07/2007
2Telomerase (Telomerase Reverse Transcriptase)IBA
04/2010 - 10/2009
2Trastuzumab (Herceptin)FDA Link
11/2009 - 08/2006
2OvalbuminIBA
09/2007 - 01/2004
2Taxoids (Taxanes)IBA
09/2006 - 10/2004
2AEG 35156IBA
09/2006 - 11/2005
2Docetaxel (Taxotere)FDA Link
09/2006 - 04/2004
2X-Linked Inhibitor of Apoptosis ProteinIBA
09/2006 - 10/2004
2Gefitinib (Iressa)FDA Link
01/2006 - 07/2004
2E2F Transcription FactorsIBA
11/2005 - 09/2003
2Therapeutic UsesIBA
02/2005 - 04/2002
2OligodeoxyribonucleotidesIBA
01/2004 - 02/2002
2Paclitaxel (Taxol)FDA LinkGeneric
12/2003 - 01/2002
2GEM231IBA
09/2003 - 07/2002
2Cyclic AMP-Dependent Protein Kinase RIalpha SubunitIBA
07/2002 - 07/2002
2Topoisomerase I InhibitorsIBA
07/2002 - 04/2002
1Potassium Channels (Potassium Channel)IBA
12/2021
1IpilimumabIBA
01/2021
1Immune Checkpoint InhibitorsIBA
01/2021
1Immunoglobulins (Immunoglobulin)IBA
09/2018
1OX40 LigandIBA
09/2018
1Apoptosis Regulatory ProteinsIBA
09/2018
1Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
09/2018
1CholesterolIBA
01/2017
1MicroRNAs (MicroRNA)IBA
01/2017
1Apolipoproteins E (ApoE)IBA
01/2017
1Urea (Carbamide)FDA LinkGeneric
11/2013
1NitrogenIBA
11/2013
1AutoantibodiesIBA
11/2013
1Toll-Like Receptor 7IBA
07/2013
1Toll-Like Receptors (Toll-Like Receptor)IBA
07/2013
1InflammasomesIBA
07/2013
1Interleukin-23 (Interleukin 23)IBA
07/2013
1InterleukinsIBA
04/2013
1Interferon-gamma (Interferon, gamma)IBA
04/2013
1Immunoglobulin G (IgG)IBA
01/2012
1Biomarkers (Surrogate Marker)IBA
10/2011

Therapy/Procedure

17Therapeutics
01/2021 - 01/2002
6Radiotherapy
01/2012 - 12/2003
5Drug Therapy (Chemotherapy)
09/2006 - 09/2003
2Immunotherapy
10/2019 - 09/2018
2Oral Administration
09/2007 - 10/2004
2Cardiopulmonary Resuscitation (CPR)
04/2004 - 05/2003
1Intradermal Injections
07/2013